Skip to main content
Equibles
CTTH logo

CTTH · Ctt Pharmaceutical Holdings, Inc. · Metrics

Track CTTH — free

Use CTTH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CTTH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.06 0.00 (-0.17%) At close · Oct 16
Rebalance outlook locked
Going-concern doubt — flagged Sep 17, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date of issuance of the audited financial statements.”
View the 10-Q filed Sep 17, 2026
Market Cap
$3.52M
Shares
59.72M
Volume · Oct 16 2999 Avg daily vol (3M) 43.28K

CTTH metrics

47 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.06
Market cap
$3.52M

Price action

20 metrics
Price change (1W)
+4.1%
Price change (30D)
+21.2%
Price change (3M)
-10.8%
Price change (6M)
-15.9%
Price change (YTD)
-2.0%
Price change (1Y)
-29.3%
Trailing year
Price change (5Y)
+24.8%
52-week high
$0.10
52-week low
$0.04
Change from 52-week high
-41.1%
Change from 52-week low
+47.3%
Annualized volatility
149.1%
Annualized volatility (3M)
—
Beta
-0.9
RSI (14D)
58.9
Price vs SMA 50
+4.0%
Price vs SMA 200
-11.2%
Avg volume (3M)
43,281
Relative volume
0.1
Average dollar volume
$2,516

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
59.72M

Valuation

12 metrics
P / E (TTM)
2.0
Trailing earnings · reciprocal yield 50.9%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
135.1
reciprocal yield 0.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-47.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$1.01M
Net income (TTM)
−$1.67M
Trailing 12 months
Diluted EPS (TTM)
$0.03
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.00

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+35.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-226.0%
Return on assets
-180.9%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$31
Latest balance sheet
Cash & equivalents
$31
Total assets
$67,434
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$103,313
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
29 / 100

Insider activity

2 metrics
Net insider buying (90D)
$4,290
Insider-sentiment score
79 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1035422 CUSIP 12651E106 Visit website